The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The companies aim to expand treatment options for millions living with metabolic disorders
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Subscribe To Our Newsletter & Stay Updated
